Cargando…

Respiratory Tract Infections in Inflammatory Bowel Disease Patients Taking Vedolizumab: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

The ongoing COVID-19 pandemic has raised concerns about the risk of SARS-CoV-2 infection in patients with Crohn’s disease (CD) and patients with ulcerative colitis (UC) taking immunosuppressants or biologics. We conducted a systematic review and meta-analysis to assess the risk of respiratory infect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marafini, Irene, Troncone, Edoardo, Rocchetti, Irene, Monteleone, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862105/ https://www.ncbi.nlm.nih.gov/pubmed/33551798 http://dx.doi.org/10.3389/fphar.2020.585732

Ejemplares similares

Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases
por: Scarozza, Patrizio, et al.
Publicado: (2020)

Precision Medicine in Inflammatory Bowel Diseases
por: Marafini, Irene, et al.
Publicado: (2021)

Metalloproteinases in Inflammatory Bowel Diseases
por: Marônek, Martin, et al.
Publicado: (2021)

Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease
por: Di Fusco, Davide, et al.
Publicado: (2019)

Involvement of Smad7 in Inflammatory Diseases of the Gut and Colon Cancer
por: Troncone, Edoardo, et al.
Publicado: (2021)

Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab
por: Scarozza, Patrizio, et al.
Publicado: (2020)

Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases
por: Marafini, Irene, et al.
Publicado: (2020)

Smoking and colorectal cancer in inflammatory bowel disease: Quantity matters?
por: Marafini, Irene, et al.
Publicado: (2023)

Endoscopic Predictors of Neoplastic Lesions in Inflammatory Bowel Diseases Patients Undergoing Chromoendoscopy
por: Lolli, Elisabetta, et al.
Publicado: (2022)

Transforming Growth Factor-β1/Smad7 in Intestinal Immunity, Inflammation, and Cancer
por: Troncone, Edoardo, et al.
Publicado: (2018)

Role of TGF-Beta and Smad7 in Gut Inflammation, Fibrosis and Cancer
por: Stolfi, Carmine, et al.
Publicado: (2020)

Interleukin-34 promotes tumorigenic signals for colon cancer cells
por: Franzè, Eleonora, et al.
Publicado: (2021)

Interleukin-34 Mediates Cross-Talk Between Stromal Cells and Immune Cells in the Gut
por: Monteleone, Giovanni, et al.
Publicado: (2022)

NPD-0414-2 and NPD-0414-24, Two Chemical Entities Designed as Aryl Hydrocarbon Receptor (AhR) Ligands, Inhibit Gut Inflammatory Signals
por: Marafini, Irene, et al.
Publicado: (2019)

Low frequency of COVID-19 in inflammatory bowel diseases
por: Marafini, Irene, et al.
Publicado: (2020)

Frequency and Predictors of Dysplasia in Pseudopolyp-like Colorectal Lesions in Patients with Long-Standing Inflammatory Bowel Disease
por: De Cristofaro, Elena, et al.
Publicado: (2023)

Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors
por: Troncone, Edoardo, et al.
Publicado: (2020)

Targeting IL-34/MCSF-1R Axis in Colon Cancer
por: Monteleone, Giovanni, et al.
Publicado: (2022)

Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials
por: Feagan, Brian G, et al.
Publicado: (2018)

Reversibility of Frail Phenotype in Patients with Inflammatory Bowel Diseases
por: Salvatori, Silvia, et al.
Publicado: (2023)

Predicting Response to Vedolizumab in Inflammatory Bowel Disease
por: Meserve, Joseph, et al.
Publicado: (2020)

Natural History of Ulcerative Colitis with Coexistent Colonic Diverticulosis
por: Marafini, Irene, et al.
Publicado: (2021)

Intestinal Taxa Abundance and Diversity in Inflammatory Bowel Disease Patients: An Analysis including Covariates and Confounders
por: Teofani, Adelaide, et al.
Publicado: (2022)

Efficacy and safety of vedolizumab for inflammatory bowel diseases: A systematic review and meta-analysis of randomized controlled trials
por: Qiu, Bo, et al.
Publicado: (2022)

High Frequency of Undiagnosed Psychiatric Disorders in Inflammatory Bowel Diseases
por: Marafini, Irene, et al.
Publicado: (2020)

Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020)

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
por: Crooks, Benjamin, et al.
Publicado: (2020)

Effect of obesity on vedolizumab response in inflammatory bowel disease
por: Levine, Louis J., et al.
Publicado: (2022)

Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study)
por: Alrashed, Fatema, et al.
Publicado: (2023)

PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Wang, Man Cai, et al.
Publicado: (2014)

Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence
por: Scribano, Maria Lia
Publicado: (2018)

Efficacy and safety of vedolizumab in the treatment of patients with inflammatory bowel disease: A systematic review and meta‑analysis of randomized controlled trials
por: Tang, Hui-Jun, et al.
Publicado: (2023)

Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab
por: Krupka, Niklas, et al.
Publicado: (2014)

Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
por: Fleisher, Mark, et al.
Publicado: (2018)

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
por: Shim, Hang Hock, et al.
Publicado: (2018)

Vedolizumab Is Safe in Elderly Veteran Patients With Inflammatory Bowel Disease
por: Leung, Kenneth, et al.
Publicado: (2021)

Association Between Celiac Disease and Cancer
por: Marafini, Irene, et al.
Publicado: (2020)

Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease
por: Schreiber, Stefan, et al.
Publicado: (2018)

Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review
por: Fang, Shengbo, et al.
Publicado: (2022)

Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases
por: Lynch, Kate D., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5v8kucj8ma4n9hrn2c142lp5n1